Navigation Links
Questcor Comments on Insurance Policy Bulletin
Date:9/19/2012

ANAHEIM, Calif., Sept.19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today commented on information regarding an insurance policy bulletin issued with respect to the Company's primary product H.P. Acthar® Gel (repository corticotropin injection) ("Acthar").

The Company is continuing to review the Clinical Policy Bulletin related to Acthar from Aetna Inc. ("Aetna").  Currently, the Company does not believe that the bulletin represents a material change in insurance coverage for Acthar by Aetna. During 2012, Aetna has accounted for approximately 5% of the Company's shipped prescriptions for Acthar.  Based on its current assessment of the Clinical Policy Bulletin, the Company does not believe that the bulletin will have a material impact on the Company's results of operations.

About Questcor 

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

•           Our reliance on Acthar for substantially all of our net sales and profits;

•           Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;

•           Our ability to receive high reimbursement levels from third party payers;

•           An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities; and

•           Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.

For more information, please visit www.questcor.com or www.acthar.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
9. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
10. Pharmaceutical Supply Chain in Japan - Periodic Drug Price Revisions by National Health Insurance Increase Competition and Squeeze Profit Margins
11. K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... ... 15, 2019 , ... Twiggy Bean, Ph.D., wanted to educate others about the ... make better decisions and become truly child focused. This objective prompted her to write ... STOP the cycle! Don’t be a divorce bully!” (published by Balboa Press), a guidebook ...
(Date:10/11/2019)... ... ... Based on data for the first eight months of the year, 2019 ... 2018. Through August 31, 7,786 deceased donors have provided 23,797 organs for transplant according ... pace, the Association of Organ Procurement Organizations (AOPO) projects 2019 could see an additional ...
(Date:10/10/2019)... ... October 10, 2019 , ... Hospice of Westchester (HOW) ... 26, at the Westchester Country Club in Rye. The event honored Grassy Sprain ... and its mission. , “In Celebration” featured live entertainment, culinary delights and a ...
Breaking Medicine Technology:
(Date:10/11/2019)... ... 11, 2019 , ... Inland Detox, Inc. has just moved to a new ... views of the Temecula Valley and it’s the perfect place for long-term residential ... private rooms as well as double occupancy rooms, a 2nd home where all treatment ...
(Date:10/10/2019)... SAN MATEO, Calif. (PRWEB) , ... October 10, 2019 , ... ... 2019 Senior Living Report on the Best and Worst Places for Seniors to Live. ... housing options, community engagement, transportation, quality of life and workforce development. , According ...
(Date:10/8/2019)... ... 2019 , ... SoCal Adolescent Wellness announces the opening of a second location ... services to better serve the families in Orange County," said Becca Moody, CEO of ... extraordinary impact this pre-intervention program has on the lives of the adolescents and families ...
(Date:10/8/2019)... ... October 08, 2019 , ... Drs. ... help patients with missing teeth restore their smiles with long-lasting dental implants ... relies on advanced i-CAT® 3D Cone Beam CT imaging, X-Guide™ software and Yomi® ...
(Date:10/8/2019)... ... October 08, 2019 , ... At the 13th Annual ... President Gregg Church will inform conference attendees how the 4medica Perfect Order ... with the right, clean patient data. The single platform interfaces to core lab ...
Breaking Medicine News(10 mins):